Technical Analysis for ACOR - Acorda Therapeutics, Inc.

Grade Last Price % Change $ Change
grade B $25.40 0.00% 0.0
ACOR closed unchanged on Friday, March 24, 2017, on 56 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical ACOR trend table...

Date Alert Name Type % Chg
Mar 24 NR7 Range Contraction 0.00%
Mar 24 Narrow Range Bar Range Contraction 0.00%
Mar 24 Doji - Bullish? Reversal 0.00%
Mar 22 Doji - Bullish? Reversal -0.59%
Mar 22 1,2,3 Pullback Bullish Bullish Swing Setup -0.59%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.59%
Mar 21 1,2,3 Pullback Bullish Bullish Swing Setup -0.78%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.78%
Mar 20 Narrow Range Bar Range Contraction -5.93%
Mar 20 Stochastic Reached Oversold Other -5.93%

Older signals for ACOR ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Is ACOR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 5 bullish, 0 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 33.0
52 Week Low 16.4
Average Volume 905,676
200-Day Moving Average 23.058
50-Day Moving Average 24.2936
20-Day Moving Average 27.1965
10-Day Moving Average 26.72
Average True Range 1.3457
ADX 32.69
+DI 23.84
-DI: 19.31
Chandelier Exit (Long, 3 ATRs) 28.9629
Chandelier Exit (Short, 3 ATRs) 28.3871
Upper Bollinger Band 29.4639
Lower Bollinger Band 24.9291
Percent B (%b) 0.1
Bandwidth 0.166742